Search 

PharmaVentures is a premier transaction advisory firm and a leading international company in partnering, M&A deals and strategic alliances. For 30 years, PharmaVentures has acted as advisor on over 900 deal related projects covering licensing, mergers, acquisitions, divestments, and joint venture activities for companies worldwide.

PharmaVentures’ deep bank of specialist experience, deal analytics and network of contacts among innovators and large pharma makes it uniquely placed to support business in all aspects of deal making and strategic planning. PharmaVentures is well known for its deep insight into deal structures and its success for generating partnering interest.

PharmaVentures’ services include:

• M&A (divestments, mergers, acquisitions, and strategic transactions)

• Licensing (in and out licensing)

• Fundraising Support

• Strategy (commercialisation, deal strategy, due diligence, market entry)

• Valuation and Positioning (licensing, M&A, and fundraising)

PHASTAR is a specialist biometrics contract research organization offering statistical consulting, clinical trial reporting, data management and data science services by providing expert consultants and managing and delivering in-house projects, FSP-style arrangements and preferred partnerships.

Our number one priority is ensuring on time, quality work: every project undertaken is supervised on methodology and utilizes internal processes designed to guarantee optimal quality, inspired by 4,000 years accumulated technical experience across the company.

PHASTAR is headquartered in London (UK) and North Carolina (US) and has 14 offices worldwide

Plich Investments is a highly focused and personalized boutique strategic advisory and transaction firm dedicated to the European pharmaceutical and biotech market. We advise on both corporate- and business- development related matters such as capital raises, license agreements and M&A and other strategic alternatives. While we remain open to all corporate structures, we pride ourselves on our ability to deliver outsized value to smaller, often family-owned, enterprises, where we can have a significant impact on their ability to penetrate US, European and other international markets and help them better monetize their innovations.

Our sweet spot of deal types is with niche or orphan medicines in the late-stage clinical development. In select cases, we have also invested our own capital in certain programs. Collectively, our team has 70 years industry experience and our execution confidence stems from closing most every type of pharma/biotech transaction, as both industry executives and board members.

Headquartered in Amsterdam, the Netherlands, our international team includes experts based in the United States and the United Kingdom.

PrecisionLife is built upon a collective ambition to improve our understanding of complex diseases and create better, more personalized therapy options so that we can help patients to live longer, healthier lives.
The PrecisionLife® platform takes a radical new approach to analysis of complex disease biology based on a wide range of patients’ genomic, clinical, and epidemiological data, enabling the discovery of richer and more useful links between patients, disease sub-groups, targets and drugs.
Our powerful patented data analytics and decision support platforms are built on a unique mathematical framework and deep experience in delivering innovative new technologies and products.
Headquartered near Oxford in the UK, we also have offices in the USA, Denmark and Poland.
Twitter Account @precisionlifeAI